Amedeo di Savoia Hospital, Infectious Diseases Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Maria Vittoria Hospital, Unit of Neurology, Asl Città di Torino, Italy.
BMC Neurol. 2021 Nov 16;21(1):449. doi: 10.1186/s12883-021-02468-2.
Tuberculous meningitis (TBM) is an important disease leading to morbidity, disability and mortality that primarily affects children and immune-depressed patients. Specific neuromarkers predicting outcomes, severity and inflammatory response are still lacking. In recent years an increasing number of evidences show a possible role for infective agents in developing neurodegenerative diseases.
We retrospectively included 13 HIV-negative patients presenting with TBM and we compared them with two control groups: one of patients with a confirmed diagnosis of AD, and one of those with syphilis where lumbar punctures excluded central nervous system involvement. Lumbar punctures were performed for clinical reasons and CSF biomarkers were routinely available: we analyzed blood brain barrier permeability (CSF to serum albumin ratio, "CSAR"), intrathecal IgG synthesis, (CSF to serum IgG ratio), inflammation (neopterin), amyloid deposition (Aβ1-42), neuronal damage (T-tau, P-tau, 14.3.3) and astrocytosis (S-100 β).
TBM patients were 83 % male and 67 % Caucasian with a median age of 51 years (24.5-63.5 IQR). Apart from altered CSAR (median value 18.4, 17.1-30.9 IQR), neopterin (14.3 ng/ml, 9.7-18.8) and IgG ratios (15.4, 7.9-24.9), patients showed very low levels of Aβ1-42 in their CSF (348.5 pg/mL,125-532.2), even lower compared to AD and controls [603 pg/mL (IQR 528-797) and 978 (IQR 789-1178)]. Protein 14.3.3 tested altered in 38.5 % cases. T-tau, P-tau and S100Beta were in the range of normality. Altered low level of Aβ1-42 correlated over time with classical TBM findings and altered neuromarkers.
CSF Biomarkers from patients with TBM were compatible with inflammation, blood brain barrier damage and impairment in amyloid-beta metabolism. Amyloid-beta could be tested as a prognostic markers, backing the routine use of available neuromarkers. To our knowledge this is the first case showing such low levels of Aβ1-42 in TBM; its accumulation, drove by neuroinflammation related to infections, can be central in understanding neurodegenerative diseases.
结核性脑膜炎(TBM)是一种重要的疾病,可导致发病率、残疾率和死亡率,主要影响儿童和免疫抑制患者。目前仍然缺乏能够预测结局、严重程度和炎症反应的特定神经标志物。近年来,越来越多的证据表明,感染因子可能在神经退行性疾病的发生中发挥作用。
我们回顾性纳入了 13 例 HIV 阴性的 TBM 患者,并将其与两组对照组进行比较:一组为确诊的 AD 患者,一组为梅毒患者,这些患者的腰椎穿刺排除了中枢神经系统受累。腰椎穿刺是出于临床原因进行的,并且常规提供 CSF 生物标志物:我们分析了血脑屏障通透性(CSF 与血清白蛋白的比值,“CSAR”)、鞘内 IgG 合成(CSF 与血清 IgG 的比值)、炎症(新蝶呤)、淀粉样蛋白沉积(Aβ1-42)、神经元损伤(Tau、P-Tau、14.3.3)和星形胶质细胞增生(S-100β)。
TBM 患者中 83%为男性,67%为白种人,中位年龄为 51 岁(24.5-63.5 IQR)。除了 CSAR(中位数为 18.4,17.1-30.9 IQR)、新蝶呤(14.3ng/ml,9.7-18.8)和 IgG 比值(15.4,7.9-24.9)异常外,患者的 CSF 中 Aβ1-42 水平非常低(348.5pg/ml,125-532.2),甚至低于 AD 和对照组[603pg/ml(IQR 528-797)和 978(IQR 789-1178)]。38.5%的病例中蛋白 14.3.3 检测异常。Tau、P-Tau 和 S100Beta 均在正常范围内。持续存在的低水平 Aβ1-42 与经典 TBM 发现和神经标志物改变相关。
TBM 患者的 CSF 生物标志物与炎症、血脑屏障损伤和淀粉样蛋白-β代谢紊乱有关。淀粉样蛋白-β可作为预后标志物进行检测,支持对现有神经标志物的常规使用。据我们所知,这是首次在 TBM 中发现如此低水平的 Aβ1-42;其在神经炎症相关感染的驱动下积累,可能是理解神经退行性疾病的关键。